Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

Effective cataract surgical coverage and outcomes

Effective cataract surgical coverage (eCSC) tracks both the uptake and the quality of cataract surgery, and WHO Member States endorsed global 2030 targets for it in 2021 [S8]. In many countries eCSC falls well below crude cataract surgical coverage (CSC), showing that surgery is reaching people but not always restoring good vision [S10] [S12]. Cost, awareness, gender and system capacity are the recurring barriers [S11].

Key points - eCSC and effective refractive error coverage were proposed as indicators of progress towards universal health coverage in eye care [S8]. - In India pooled CSC was 57% but eCSC only 36%, a relative quality gap of 37% [S12]. - Average CSC was around 50% or lower in most countries, and the cataract surgical rate ranged from 36 to 12 800 per million population [S10]. - Women had lower access to cataract surgery in India and South Asia [S4] [S6], but no gender difference was found in Latin America [S9]. - In one cluster RCT in rural China, waiving the surgical fee increased uptake (RR 1.94; low-certainty evidence), whereas information and counselling alone had little or no effect [S3].

Evidence last checked: 2026-10-17 (PubMed abstracts).

Red flags: signs that need urgent action

• A large gap between CSC and eCSC: surgery is being done but outcomes are poor; quality improvement must accompany efforts to increase coverage [S12].
• Low coverage in a region: the Northeast of India had CSC 36% and eCSC 23% [S12]; CSC at 3/60 was 24.1% in Peru and eCSC 14.8% in Guatemala [S7].
• Women left behind: in Africa CSC was lower in females in 88.2% of studies [S2]; in India women had 69% higher odds of being cataract blind [S4].
• Low intraocular lens (IOL) use: good visual outcomes correlated with IOL use in sub-Saharan Africa [S1].
• Service disruption: COVID-19 reduced cataract surgery rates in many countries [S10].

Recognise it: the indicators

• CSC is a coverage measure reported at visual acuity thresholds such as <3/60 and <6/18, per person or per eye [S6] [S9].
• eCSC is designed to track both uptake and quality of cataract services; WHO convened expert consultations to standardise its definitions and measurement [S8]. In many countries it deviates from CSC [S10].
• Relative quality gap (RQG) expresses how much of CSC is lost to poor outcomes [S12].
• Cataract surgical rate (CSR) counts operations per million population and can be calculated from ministry of health surgical numbers [S7] [S10].
• Burden: cataract was the principal cause of blindness in 15 of 17 sub-Saharan African surveys [S1] and caused 29.8% to 77.6% of blindness in Latin American studies [S7].

Confirm it: measuring coverage

• The Rapid Assessment of Avoidable Blindness (RAAB) is a relatively simple, low-cost survey of the prevalence and causes of visual loss; at least 331 had been done in 79 countries [S5].
• RAAB is moving to mobile, cloud-based data collection with more emphasis on using the data for planning [S5].
• RAAB and Rapid Assessment of Cataract Surgical Services data can be reanalysed to calculate sex inequality in CSC and eCSC [S7].
• High heterogeneity between surveys within one country supports district-level analysis rather than a single national figure [S12].

Manage it: improving coverage and quality at each resource tier

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

• Identify people with vision-impairing cataract in the community and refer them; weak referral pathways and inconsistent outreach are community-level barriers [S11].
• Address costs and fear: direct and indirect costs, limited awareness and fear of poor outcomes are the commonest patient-level barriers [S11].
• Make a deliberate effort to reach women [S2] [S4] [S6].

Tier B (general eye clinic)

• Use IOLs, given their link with good visual outcomes [S1].
• Audit your own visual outcomes; a gap between CSC and eCSC reflects surgical quality [S10] [S12].
• Reduce financial barriers where possible: fee waivers increased uptake in one trial [S3]; transport support and subsidies are recommended by a 2025 review [S11].

Tier C (specialist centre and planners)

• Track eCSC alongside CSC, since 2030 targets are set for eCSC [S8].
• Run district-focused planning and target low-coverage regions [S12].
• Invest in workforce, theatre capacity, equipment and consumables, and scheduling, the main system-level barriers [S11].
• Train ophthalmologists, distribute human resources better and include vision services in universal health coverage [S7].
• Government insurance support and suitable services can increase cataract surgery [S10].

Refer when

Pitfalls

• Counting operations without measuring outcomes [S10] [S12].
• Reporting one national figure that hides regional gaps [S12].
• Assuming information alone will raise uptake [S3].
• Ignoring gender: patterns differ by region [S4] [S9].
• Focusing on one barrier when they are multifactorial and interlinked [S11].

Evidence notes

• Intervention evidence is very thin: only two trials, both in rural China, with unclear risk of bias and no data on coverage or outcomes [S3].
• Gender findings conflict by region: female disadvantage in India and South Asia [S4] [S6], none in Latin America [S9], where median gender inequality in CSC and eCSC was below 1% [S7].
• Most other sources are cross-sectional surveys and narrative reviews.
• Not covered by these sources: the exact eCSC formula and visual outcome threshold, the numerical 2030 target, and outcome monitoring tools.

Related articles

• Manual small-incision cataract surgery
• Global eye health: blindness and vision impairment

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.